Gilead-Teva IP Deal Struck Despite Invalidity Issues, Jury Told

By Dorothy Atkins (June 9, 2023, 11:31 PM EDT) -- Two experts took the stand Friday on behalf of indirect drug buyers in a California federal antitrust trial over claims Teva struck an illegal "pay for delay" patent deal with Gilead over two HIV medications, testifying that Gilead's patents covered obvious technology and Teva knew that before entering the deal....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!